Literature DB >> 35588343

CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.

Ke-Da Yang1, Ying Wang1, Fan Zhang2, Qing-Ling Li1, Bai-Hua Luo1, De-Yun Feng1, Zhi-Jun Zeng3.   

Abstract

This study aimed to investigate the role of cancer-associated fibroblast (CAF)-derived midkine (MK) in cisplatin (DDP) resistance. The primary cultures of CAFs and non-cancer fibroblasts (NFs) were isolated and purified. The DDP-resistant gastric cancer (GC) cells were cultured with CAF-conditioned medium. QRT-PCR and Elisa assays were employed to determine MK expression. The expression of ST7-AS1 was measured by qRT-PCR. The impact of CAFs, MK, and ST7-AS1 silencing on DDP resistance was determined by MTT and Annexin V/PI staining assay. Expression of EMT markers and PI3K/AKT was determined by Western blot and qRT-PCR. The role of MK in DDP resistance was confirmed in a xenograft model. Incubation with CAF-conditioned medium increased the IC50 to DDP. Also, incubation with CAF-conditioned medium increased cell viability, reduced cell apoptosis, and promoted EMT in DDP-resistant GC cells, which were all blocked with MK neutralization antibody treatment. MK increased the DDP resistance and upregulated the expression of ST7-AS1 in DDP-resistant GC cells. Additionally, ST7-AS1 knockdown increased the sensitivity to DDP by inhibiting EMT. Moreover, ST7-AS1 knockdown significantly decreased the phosphorylation of PI3K and AKT, and suppressed EMT, which were restored by MK addition. Finally, MK promoted tumor growth and DDP resistance in a mice model bearing the SGC-7901/DDP xenografts. CAF-derived MK promotes EMT-mediated DDP resistance via upregulation of ST7-AS1 and activation of PI3K/AKT pathway.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  EMT; Long non-coding RNA ST7-AS1; Midkine; PI3K/AKT; Xenograft

Year:  2022        PMID: 35588343     DOI: 10.1007/s11010-022-04436-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  33 in total

Review 1.  Cisplatin resistance: preclinical findings and clinical implications.

Authors:  Beate Köberle; Maja T Tomicic; Svetlana Usanova; Bernd Kaina
Journal:  Biochim Biophys Acta       Date:  2010-07-17

2.  Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action.

Authors:  M Lorente; S Torres; M Salazar; A Carracedo; S Hernández-Tiedra; F Rodríguez-Fornés; E García-Taboada; B Meléndez; M Mollejo; Y Campos-Martín; S A Lakatosh; J Barcia; M Guzmán; G Velasco
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

3.  Identification of midkine as a mediator for intercellular transfer of drug resistance.

Authors:  Bernard L Mirkin; Sandra Clark; Xin Zheng; Fei Chu; Bryan D White; Marianne Greene; Abdelhadi Rebbaa
Journal:  Oncogene       Date:  2005-07-21       Impact factor: 9.867

4.  Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer.

Authors:  Roya Navab; Dan Strumpf; Bizhan Bandarchi; Chang-Qi Zhu; Melania Pintilie; Varune Rohan Ramnarine; Emin Ibrahimov; Nikolina Radulovich; Lisa Leung; Malgorzata Barczyk; Devang Panchal; Christine To; James J Yun; Sandy Der; Frances A Shepherd; Igor Jurisica; Ming-Sound Tsao
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-07       Impact factor: 11.205

Review 5.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

6.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Keith F Fournier; Huamin Wang; Lauren Marquis; James L Abbruzzese; Gary E Gallick; Craig D Logsdon; David J McConkey; Woonyoung Choi
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

7.  CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer.

Authors:  Kenichi Suda; Isao Murakami; Hui Yu; Jihye Kim; Aik-Choon Tan; Hiroshi Mizuuchi; Leslie Rozeboom; Kim Ellison; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  Mol Cancer Ther       Date:  2018-07-26       Impact factor: 6.261

8.  EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Authors:  Alexandria M Haslehurst; Madhuri Koti; Moyez Dharsee; Paulo Nuin; Ken Evans; Joseph Geraci; Timothy Childs; Jian Chen; Jieran Li; Johanne Weberpals; Scott Davey; Jeremy Squire; Paul C Park; Harriet Feilotter
Journal:  BMC Cancer       Date:  2012-03-19       Impact factor: 4.430

9.  Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells.

Authors:  Dongya Zhang; Liang Ding; Yi Li; Jing Ren; Guoping Shi; Yong Wang; Shuli Zhao; Yanhong Ni; Yayi Hou
Journal:  Sci Rep       Date:  2017-11-24       Impact factor: 4.379

Review 10.  Gastric cancer: epidemiology, prevention, classification, and treatment.

Authors:  Robert Sitarz; Małgorzata Skierucha; Jerzy Mielko; G Johan A Offerhaus; Ryszard Maciejewski; Wojciech P Polkowski
Journal:  Cancer Manag Res       Date:  2018-02-07       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.